GlassScriptPhysician profile
Katherine Mae Casadaban
NPI 1215553664
$5,043.34
in general payments reported to CMS, 2019-2025
22 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $90.73 · 2021: $743 · 2022: $455 · 2023: $1,061 · 2024: $979 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Entertainment: $570 · Honoraria: $32.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,152.22 |
| Entertainment | $569.68 |
| Honoraria | $32.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $619.05 | 2022-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Optos, INC. | $569.68 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $437.17 | 2024-2025 | Xdemvy |
| Abbvie INC. | $359.39 | 2022-2025 | Vuity, Lumigan |
| Mallinckrodt Hospital Products INC. | $340.26 | 2020-2024 | Acthar |
| Oyster Point Pharma, INC. | $323.71 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $308.88 | 2023-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $268.85 | 2020-2021 | |
| Coopervision INC. | $256.88 | 2022-2024 | Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $252.59 | 2021-2023 | Acuvue |
| Allergan, INC. | $224.38 | 2021-2022 | |
| Harrow Eye, LLC | $183.82 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $177.09 | 2022-2025 | Xiidra, Miebo |
| Biotissue Holdings INC. | $158.06 | 2022-2025 | |
| Rxsight INC | $135.16 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $121.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $111.46 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $51.57 | 2025 | |
| Aerie Pharmaceuticals, INC. | $48.16 | 2021 | |
| Sun Pharmaceutical Industries INC. | $46.50 | 2020-2021 | |
| Glaukos Corporation | $32.14 | 2021 | |
| Alimera Sciences, INC. | $17.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Casadaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.